drugset
Drugs / Cervavac
last change 6 days ago re-read 9 days ago

Cervavac

also known as SIIPL qHPV vaccine

Vaccine

Developed for
human papilloma virus infection
Investigated by
Bill and Melinda Gates Foundation · Serum Institute of India Pvt. Ltd.

Trials 1

today NCT06281119 · Ph 3
20262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06281119 Oct 2025 → Dec 2026 expected human papilloma virus infection Serum Institute of India Pvt. Ltd. Active not recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2026-10-05 Serum Institute of India Pvt. Ltd. Regulatory Serum Institute of India's HPV Vaccine Cervavac® receives WHO Prequalification seruminstitute.com ↗
CERVAVAC ® , India’s first indigenously developed gender-neutral Quadrivalent Human Papillomavirus vaccine (qHPV) developed by Serum Institute of India receives prequalification by the World Health Organization (WHO).

All press releases naming this drug 3 releases

DateIssuerRelease

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CERVAVAC “Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years” NCT06281119 ↗
1

NCT06281119 ↗
Known as SIIPL qHPV vaccine “Clinical Study to Evaluate SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years” NCT06281119 ↗
Modality Vaccine “Recombinant Quadrivalent Human Papillomavirus (Types 6,11 16, 18) Vaccine manufactured by Serum Institute of India Pvt Ltd administered as three doses at day 0, 60 and 180.” NCT06281119 ↗